The North America Diabetic Neuropathy Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2024-2031).
The US market dominated the North America Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,993 million by 2031. The Canada market is experiencing a CAGR of 9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2024 - 2031).
An area of notable progress in the management of diabetic neuropathy pertains to the creation of innovative pharmacological interventions. Several medications have been approved for this purpose, including anticonvulsants, antidepressants, and opioids.
Additionally, these approaches include physical therapy, occupational therapy, and lifestyle modifications such as diet and exercise. The primary objectives are to enhance muscular strength and flexibility, alleviate pain and discomfort, and elevate the quality of life for those afflicted with diabetic neuropathy.
According to the National Library of Medicine, diabetes mellitus is particularly significant in Mexico, where it ranks as the sixth highest for the number of adults affected, with 12.8 million individuals diagnosed with the disease in 2019. This number is projected to rise significantly, reaching an estimated 22.3 million by the year 2045. The Mexican government implemented a program (El Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes Mellitus Tipo 2, SVEHDMT2) to monitor hospital attendance by people suffering from type 2 diabetes mellitus.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,993 million by 2031. The Canada market is experiencing a CAGR of 9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2024 - 2031).
An area of notable progress in the management of diabetic neuropathy pertains to the creation of innovative pharmacological interventions. Several medications have been approved for this purpose, including anticonvulsants, antidepressants, and opioids.
Additionally, these approaches include physical therapy, occupational therapy, and lifestyle modifications such as diet and exercise. The primary objectives are to enhance muscular strength and flexibility, alleviate pain and discomfort, and elevate the quality of life for those afflicted with diabetic neuropathy.
According to the National Library of Medicine, diabetes mellitus is particularly significant in Mexico, where it ranks as the sixth highest for the number of adults affected, with 12.8 million individuals diagnosed with the disease in 2019. This number is projected to rise significantly, reaching an estimated 22.3 million by the year 2045. The Mexican government implemented a program (El Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes Mellitus Tipo 2, SVEHDMT2) to monitor hospital attendance by people suffering from type 2 diabetes mellitus.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Distribution Channel- Hospitals Pharmacies
- Retail Pharmacies
- Others
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Opioid
- Capsaicin
- Others
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America Diabetic Neuropathy Treatment Market by Distribution Channel
Chapter 5. North America Diabetic Neuropathy Treatment Market by Drug Class
Chapter 6. North America Diabetic Neuropathy Treatment Market by Disorder Type
Chapter 7. North America Diabetic Neuropathy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
